CA-RECVUE
14.1.2021 15:02:34 CET | Business Wire | Press release
RecVue, provider of Order Lifecycle Management (OLM) solutions designed to modernize the complex order-to-cash (O2C) processes for enterprises, has raised $13 million in a Series A round. Cota Capital led the round, in which Epic Ventures and Long Light Capital also participated. RecVue will use the funding to expand its engineering, go-to-market efforts and international presence.
“We offer the industry’s only suite of OLM solutions that are purpose-built to address the growing gap between front- and back-office business processes,” said Nishant Nair, founder and CEO of RecVue. “This fundraising round provides a dynamic foundation for rapid growth in our go-to-market operations as well as allowing us to quickly add new capabilities to our OLM suite of applications to scale to the $150 billion revenue under management target.”
Bobby Yazdani, managing partner for Cota Capital, added “Since its launch, RecVue’s technology has been transforming the order-to-cash process, helping customers innovate and operate new business models and manage complex revenue streams at unprecedented scale, speed and efficiency. The RecVue leadership team has crafted a powerful strategic plan that has them poised to transform order-to-cash needs of hundreds of large enterprises and process billions of transactions over the next several years.”
The “middle office” is the command center for the enterprise, encompassing all the business functions that sit between the traditional front-and-back systems -- from initial engagement to managing relationships and complex order-to-cash processes such as billing, revenue management and channel partner compensation. The middle office presents a largely untapped opportunity to harness revenue potential by leveraging back-office data to influence front-office business decisions.
Yet, many organizations today are experiencing a growing “middle office” gap between their customer-facing front-office CRM systems and transaction-heavy, back-office ERP systems. Faced with data silos, fragmented and often manual processes, and custom-built applications and spreadsheets, many companies are forced to do complicated data integrations to make CRM and ERP systems work together.
RecVue addresses the middle office gap more efficiently and effectively by fully automating the complex order-to-cash processes for billing, revenue, accruals management and channel partner payments. Additionally, RecVue provides robust analytics and reporting. Customers using RecVue’s unified approach have benefited by closing their books earlier, reducing their compliance risk, and significantly lowering their total cost and overhead.
“We’ve been able to significantly reduce the cost and complexity of our revenue operations using RecVue’s OLM suite of applications,” said Philipp Lustenberger, CFO, General Assembly, part of Adecco group. “Automating, streamlining, and optimizing our order-to-cash process has helped our finance and operations teams focus more on the strategic challenges that we face.”
Mark Thomason, IDC’s Research Director for Digital Business Models and Monetization said, “The COVID-19 pandemic has accelerated the trend toward recurring business models and selling over new digital channels, including multi-partner marketplaces. This has increased monetization complexity and the need to scale quickly. Future-focused companies are adopting agile monetization systems such as RecVue’s OLM suite to easily implement complex recurring business models, automate the order-to-cash process, and easily manage partner settlement to enable the goal of continuous accounting close.”
About RecVue
RecVue empowers enterprises to modernize their billing and revenue operations at speed and scale by harnessing previously untapped revenue potential and leveraging front-office CRM data and back-office ERP systems to influence business decisions. Trusted by the world’s leading companies in business services, transportation and logistics, financial services, media and technology, including Hertz, General Assembly, ACI Worldwide, and Textainer, RecVue’s suite of purpose-built cloud applications enable enterprises to expand recurring revenue and automate complex order-to-cash (O2C) processes. For more information, visit www.recvue.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005100/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom